Anti-abortion groups and some medical professionals are criticizing the federal judge's decision, warning that it removes critical safety safeguards for women. They argue that the FDA's in-person dispensing requirement ensured proper monitoring and follow-up care, and that the ruling could lead to unsupervised use of a strong drug.
Concerns focus on the risk of incomplete abortion, hemorrhage, and lack of emergency access. While complications are rare, opponents say the restrictions were a reasonable precaution. They also question the judge's authority to second-guess FDA safety determinations, a role traditionally left to experts.
The ruling comes amid a fragmented abortion landscape after Dobbs. In states with bans, the decision may have no effect, but in states that protect access, it could encourage more medication abortions without sufficient oversight. Some worry that this will fuel political backlash and lead to stricter state laws.
Critics also point to the FDA's original approval conditions, which were based on clinical trials. They argue that changing the rules without new evidence of safety in wider use is premature. The case is likely headed to higher courts, where opponents hope the ruling will be reversed.